Schedule 13G ownership disclosure
Enanta Pharmaceuticals Inc
COMMON STOCK, Par Value $0.01 Per Share · CUSIP: 29251M106
Event date: 2024-02-22
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Krensavage Asset Management, LLC
Shares: 1,086,024.00 · Class: 5.1%
- KRENSAVAGE PARTNERS LP
Shares: 979,910.00 · Class: 4.6%
- Krensavage Partners Too, LP
Shares: 106,114.00 · Class: 0.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001609251-24-000004
- Form type
- SCHEDULE 13G
- Filer
- ENANTA PHARMACEUTICALS INC
- CIK
- CIK 1177648
- Filed
- Feb 27, 2024
- Reporting period
- Feb 22, 2024
- Description
- Schedule 13G beneficial ownership